BACKGROUND: C-X-C chemokine receptor 4 (CXCR4) and CXCR7 are 7-transmembrane chemokine receptors of the stroma-derived factor (SDF-1). CXCR4, but not CXCR7, has been examined in bladder cancer (BCa). This study examined the functional and clinical significance of CXCR7 in BCa. METHODS: CXCR4 and CXCR7 levels were measured in BCa cell lines, tissues (normal = 25; BCa = 44), and urine specimens (n = 186) by quantitative polymerase chain reaction and/or immunohistochemistry. CXCR7 function in BCa cells were examined by transient transfections using a CXCR7 expression vector or small interfering RNA. RESULTS: In BCa cell lines, CXCR7 messenger RNA levels were 5- to 37-fold higher than those for CXCR4. Transient overexpression of CXCR7 in BCa cell lines promoted growth and chemotactic motility. CXCR7 colocalized and formed a functional complex with epidermal growth factor receptor, phosphoinositide 3-kinase/Akt, Erk, and src and induced their phosphorylation. CXCR7 also induced up-regulation of cyclin-D1 and bcl-2. Suppression of CXCR7 expression reversed these effects and induced apoptosis. CXCR7 messenger RNA levels and CXCR7 staining scores were significantly (5- to 10-fold) higher in BCa tissues than in normal tissues (P < .001). CXCR7 expression independently associated with metastasis (P = .019) and disease-specific mortality (P = .03). CXCR7 was highly expressed in endothelial cells in high-grade BCa tissues when compared to low-grade BCa and normal bladder. CXCR7 levels were elevated in exfoliated urothelial cells from high-grade BCa patients (P = .0001; 90% sensitivity; 75% specificity); CXCR4 levels were unaltered. CONCLUSIONS: CXCR7 promotes BCa cell proliferation and motility plausibly through epidermal growth factor receptor receptor and Akt signaling. CXCR7 expression is elevated in BCa tissues and exfoliated cells and is associated with high-grade and metastasis.
BACKGROUND:C-X-C chemokine receptor 4 (CXCR4) and CXCR7 are 7-transmembrane chemokine receptors of the stroma-derived factor (SDF-1). CXCR4, but not CXCR7, has been examined in bladder cancer (BCa). This study examined the functional and clinical significance of CXCR7 in BCa. METHODS:CXCR4 and CXCR7 levels were measured in BCa cell lines, tissues (normal = 25; BCa = 44), and urine specimens (n = 186) by quantitative polymerase chain reaction and/or immunohistochemistry. CXCR7 function in BCa cells were examined by transient transfections using a CXCR7 expression vector or small interfering RNA. RESULTS: In BCa cell lines, CXCR7 messenger RNA levels were 5- to 37-fold higher than those for CXCR4. Transient overexpression of CXCR7 in BCa cell lines promoted growth and chemotactic motility. CXCR7 colocalized and formed a functional complex with epidermal growth factor receptor, phosphoinositide 3-kinase/Akt, Erk, and src and induced their phosphorylation. CXCR7 also induced up-regulation of cyclin-D1 and bcl-2. Suppression of CXCR7 expression reversed these effects and induced apoptosis. CXCR7 messenger RNA levels and CXCR7 staining scores were significantly (5- to 10-fold) higher in BCa tissues than in normal tissues (P < .001). CXCR7 expression independently associated with metastasis (P = .019) and disease-specific mortality (P = .03). CXCR7 was highly expressed in endothelial cells in high-grade BCa tissues when compared to low-grade BCa and normal bladder. CXCR7 levels were elevated in exfoliated urothelial cells from high-grade BCa patients (P = .0001; 90% sensitivity; 75% specificity); CXCR4 levels were unaltered. CONCLUSIONS:CXCR7 promotes BCa cell proliferation and motility plausibly through epidermal growth factor receptor receptor and Akt signaling. CXCR7 expression is elevated in BCa tissues and exfoliated cells and is associated with high-grade and metastasis.
Authors: J R Masters; P J Hepburn; L Walker; W J Highman; L K Trejdosiewicz; S Povey; M Parkar; B T Hill; P R Riddle; L M Franks Journal: Cancer Res Date: 1986-07 Impact factor: 12.701
Authors: C D'Alterio; C Consales; M Polimeno; R Franco; L Cindolo; L Portella; M Cioffi; R Calemma; L Marra; L Claudio; S Perdonà; S Pignata; G Facchini; G Cartenì; N Longo; L Pucci; A Ottaiano; S Costantini; G Castello; S Scala Journal: Curr Cancer Drug Targets Date: 2010-11 Impact factor: 3.428
Authors: Mario W Kramer; Diogo O Escudero; Soum D Lokeshwar; Roozbeh Golshani; Obi O Ekwenna; Kristell Acosta; Axel S Merseburger; Mark Soloway; Vinata B Lokeshwar Journal: Cancer Date: 2010-10-19 Impact factor: 6.860
Authors: Margitta M Retz; Sukhvinder S Sidhu; Ekaterina Blaveri; Sheena C Kerr; Gregory M Dolganov; Jan Lehmann; Peter Carroll; Jeff Simko; Frederic M Waldman; Carol Basbaum Journal: Int J Cancer Date: 2005-03-20 Impact factor: 7.396
Authors: Daley S Morera; Sarrah L Hasanali; Daniel Belew; Santu Ghosh; Zachary Klaassen; Andre R Jordan; Jiaojiao Wang; Martha K Terris; Roni J Bollag; Axel S Merseburger; Arnulf Stenzl; Mark S Soloway; Vinata B Lokeshwar Journal: J Urol Date: 2019-05-21 Impact factor: 7.450
Authors: Jinbo Chen; Y U Cui; Longfei Liu; Chao Li; Yunhua Tang; X U Zhou; Lin Qi; Xiongbing Zu Journal: Oncol Lett Date: 2015-11-18 Impact factor: 2.967
Authors: Li-Mei Chen; Myron Chang; Yunfeng Dai; Karl X Chai; Lars Dyrskjøt; Marta Sanchez-Carbayo; Tibor Szarvas; Ellen C Zwarthoff; Vinata Lokeshwar; Carmen Jeronimo; Alexander S Parker; Shanti Ross; Michael Borre; Torben F Orntoft; Tobias Jaeger; Willemien Beukers; Luis E Lopez; Rui Henrique; Paul R Young; Virginia Urquidi; Steve Goodison; Charles J Rosser Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-11 Impact factor: 4.254
Authors: Miguel Gosalbez; Marie C Hupe; Soum D Lokeshwar; Travis J Yates; John Shields; Muthu K Veerapen; Axel S Merseburger; Charles J Rosser; Mark S Soloway; Vinata B Lokeshwar Journal: J Urol Date: 2013-11-26 Impact factor: 7.450
Authors: Travis J Yates; Luis E Lopez; Soum D Lokeshwar; Nicolas Ortiz; Georgios Kallifatidis; Andre Jordan; Kelly Hoye; Norman Altman; Vinata B Lokeshwar Journal: J Natl Cancer Inst Date: 2015-04-13 Impact factor: 13.506
Authors: Nicole Salazar; Daniel Muñoz; Georgios Kallifatidis; Rajendra K Singh; Mercè Jordà; Bal L Lokeshwar Journal: Mol Cancer Date: 2014-08-28 Impact factor: 27.401